Patients with localized prostate cancer may face substantial out-of-pocket expenses up to 24 months after diagnosis, a survey suggests.
Perioperative outcomes of cytoreductive nephrectomy for metastatic renal cell carcinoma improved from 2005 to 2019.
Patients diagnosed with prostate cancer during the first year of the COVID-19 pandemic were more likely to have higher-risk disease and less likely to receive definitive treatment.
Men with oligometastatic castration-sensitive prostate cancer have improved outcomes when ADT is added to MDT.
Patients with locally advanced and low metastatic burden prostate cancer have similar oncologic outcomes when treated with ADT alone.
Percutaneous cryoablation of localized T1a RCC provides long-term oncologic control with a low rate of complications, according to researchers.
Occupational exposure to the solvents benzene, toluene, and zylene can increase the risk of bladder cancer, a new study suggests.
A recent study revealed a racial disparity in the use of guideline-concordant treatment for metastatic prostate cancer.